Salva R Yurista1,2, Shi Chen3,4, Aidan Welsh3,4, W H Wilson Tang5,6, Christopher T Nguyen3,4,5,7,6,8. 1. Cardiovascular Research Center, Corrigan Minehan Heart Center, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Boston, MA, 02129, USA. syurista@mgh.harvard.edu. 2. Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA. syurista@mgh.harvard.edu. 3. Cardiovascular Research Center, Corrigan Minehan Heart Center, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Boston, MA, 02129, USA. 4. Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA. 5. Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA. 6. Cardiovascular Innovation Research Center, Cleveland Clinic, Cleveland, OH, USA. 7. Division of Health Science Technology, Harvard-Massachusetts Institute of Technology, Cambridge, MA, USA. 8. Imaging Institute, Cleveland Clinic, Cleveland, OH, USA.
Abstract
PURPOSE OF REVIEW: We review the clinical benefits of altering myocardial substrate metabolism in heart failure. RECENT FINDINGS: Modulation of cardiac substrates (fatty acid, glucose, or ketone metabolism) offers a wide range of therapeutic possibilities which may be applicable to heart failure. Augmenting ketone oxidation seems to offer great promise as a new therapeutic modality in heart failure. The heart has long been recognized as metabolic omnivore, meaning it can utilize a variety of energy substrates to maintain adequate ATP production. The adult heart uses fatty acid as a major fuel source, but it can also derive energy from other substrates including glucose and ketone, and to some extent pyruvate, lactate, and amino acids. However, cardiomyocytes of the failing heart endure remarkable metabolic remodeling including a shift in substrate utilization and reduced ATP production, which account for cardiac remodeling and dysfunction. Research to understand the implication of myocardial metabolic perturbation in heart failure has grown in recent years, and this has raised interest in targeting myocardial substrate metabolism for heart failure therapy. Due to the interdependency between different pathways, the main therapeutic metabolic approaches include inhibiting fatty acid uptake/fatty acid oxidation, reducing circulating fatty acid levels, increasing glucose oxidation, and augmenting ketone oxidation.
PURPOSE OF REVIEW: We review the clinical benefits of altering myocardial substrate metabolism in heart failure. RECENT FINDINGS: Modulation of cardiac substrates (fatty acid, glucose, or ketone metabolism) offers a wide range of therapeutic possibilities which may be applicable to heart failure. Augmenting ketone oxidation seems to offer great promise as a new therapeutic modality in heart failure. The heart has long been recognized as metabolic omnivore, meaning it can utilize a variety of energy substrates to maintain adequate ATP production. The adult heart uses fatty acid as a major fuel source, but it can also derive energy from other substrates including glucose and ketone, and to some extent pyruvate, lactate, and amino acids. However, cardiomyocytes of the failing heart endure remarkable metabolic remodeling including a shift in substrate utilization and reduced ATP production, which account for cardiac remodeling and dysfunction. Research to understand the implication of myocardial metabolic perturbation in heart failure has grown in recent years, and this has raised interest in targeting myocardial substrate metabolism for heart failure therapy. Due to the interdependency between different pathways, the main therapeutic metabolic approaches include inhibiting fatty acid uptake/fatty acid oxidation, reducing circulating fatty acid levels, increasing glucose oxidation, and augmenting ketone oxidation.
Authors: G Paolisso; A Gambardella; D Galzerano; A D'Amore; P Rubino; M Verza; P Teasuro; M Varricchio; F D'Onofrio Journal: Metabolism Date: 1994-02 Impact factor: 8.694
Authors: Kenneth C Bedi; Nathaniel W Snyder; Jeffrey Brandimarto; Moez Aziz; Clementina Mesaros; Andrew J Worth; Linda L Wang; Ali Javaheri; Ian A Blair; Kenneth B Margulies; J Eduardo Rame Journal: Circulation Date: 2016-01-27 Impact factor: 29.690
Authors: Mamas A Mamas; Matthew Sperrin; Margaret C Watson; Alasdair Coutts; Katie Wilde; Christopher Burton; Umesh T Kadam; Chun Shing Kwok; Allan B Clark; Peter Murchie; Iain Buchan; Philip C Hannaford; Phyo K Myint Journal: Eur J Heart Fail Date: 2017-05-03 Impact factor: 15.534